Health Care • Biotechnology: Pharmaceutical Preparations
$45.08 ▲ +0.30
(+0.67%)
MKT CAP: $3.30B • VOL: 909.5K
52W L $15 52W H $62
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
ELVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$119.7M | -$104.6M | -$83.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$103.7M | -$89.0M | -$71.6M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$70.3M | -$73.2M | -$61.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$70.3M | -$73.2M | -$61.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -26.2% | -44.5% | — |
| Cash & Short-Term Equivalents | $98.9M | $124.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $459.6M | $309.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELVN.